Comparison of Recombinant Human Thyroid-Stimulating Hormone and Thyroid Hormone Withdrawal for 131 I Therapy in Patients With Intermediate- to High-Risk Thyroid Cancer : A Systematic Review and Meta-analysis
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved..
BACKGROUND: This meta-analysis and systematic review aimed to evaluate the therapeutic efficacy and advantages associated with the use of recombinant human thyroid-stimulating hormone (rhTSH) for radioactive iodine (RAI) therapy in patients with intermediate- to high-risk differentiated thyroid cancer.
PATIENTS AND METHODS: MEDLINE, EMBASE, and Cochrane databases were searched to identify relevant articles reporting clinical outcomes of rhTSH compared with thyroid hormone withdrawal (THW) in patients with intermediate- to high-risk differentiated thyroid cancer published between January 2012 and June 2023. Meta-analyses were performed (PROSPERO registration number: CRD42022340915) to assess the success rate of radioiodine remnant ablation (RRA) in patients with intermediate to high risk and determine the disease control rate among patients with distant metastases, evaluated using the RECIST criteria.
RESULTS: Thirteen studies involving 1858 patients were included in the meta-analysis. Pooled analyses revealed significantly higher overall RRA success rate in the rhTSH group compared with the THW group, with a risk ratio (RR) of 1.12 (95% confidence interval [CI], 1.01-1.25). However, in the subgroup analysis of high-risk patients, pooled analyses showed no significant differences in RRA success rate between the rhTSH group compared with the THW group with a pooled RR of 1.05 (95% CI, 0.88-1.24). In patients with distant metastases, there were no significant differences in the disease control rate between groups, with a pooled RR of 1.06 (95% CI, 0.78-1.44).
CONCLUSIONS: rhTSH for RAI therapy is a practical option for RAI therapy in patients with intermediate- to high-risk thyroid cancer, including those with distant metastases.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
---|---|
Enthalten in: |
Clinical nuclear medicine - 49(2024), 3 vom: 01. Feb., Seite e96-e104 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Park, Sohyun [VerfasserIn] |
---|
Links: |
---|
Themen: |
9002-71-5 |
---|
Anmerkungen: |
Date Completed 05.02.2024 Date Revised 05.02.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1097/RLU.0000000000005022 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM367616882 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM367616882 | ||
003 | DE-627 | ||
005 | 20240205232057.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240126s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1097/RLU.0000000000005022 |2 doi | |
028 | 5 | 2 | |a pubmed24n1281.xml |
035 | |a (DE-627)NLM367616882 | ||
035 | |a (NLM)38271262 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Park, Sohyun |e verfasserin |4 aut | |
245 | 1 | 0 | |a Comparison of Recombinant Human Thyroid-Stimulating Hormone and Thyroid Hormone Withdrawal for 131 I Therapy in Patients With Intermediate- to High-Risk Thyroid Cancer |b A Systematic Review and Meta-analysis |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 05.02.2024 | ||
500 | |a Date Revised 05.02.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved. | ||
520 | |a BACKGROUND: This meta-analysis and systematic review aimed to evaluate the therapeutic efficacy and advantages associated with the use of recombinant human thyroid-stimulating hormone (rhTSH) for radioactive iodine (RAI) therapy in patients with intermediate- to high-risk differentiated thyroid cancer | ||
520 | |a PATIENTS AND METHODS: MEDLINE, EMBASE, and Cochrane databases were searched to identify relevant articles reporting clinical outcomes of rhTSH compared with thyroid hormone withdrawal (THW) in patients with intermediate- to high-risk differentiated thyroid cancer published between January 2012 and June 2023. Meta-analyses were performed (PROSPERO registration number: CRD42022340915) to assess the success rate of radioiodine remnant ablation (RRA) in patients with intermediate to high risk and determine the disease control rate among patients with distant metastases, evaluated using the RECIST criteria | ||
520 | |a RESULTS: Thirteen studies involving 1858 patients were included in the meta-analysis. Pooled analyses revealed significantly higher overall RRA success rate in the rhTSH group compared with the THW group, with a risk ratio (RR) of 1.12 (95% confidence interval [CI], 1.01-1.25). However, in the subgroup analysis of high-risk patients, pooled analyses showed no significant differences in RRA success rate between the rhTSH group compared with the THW group with a pooled RR of 1.05 (95% CI, 0.88-1.24). In patients with distant metastases, there were no significant differences in the disease control rate between groups, with a pooled RR of 1.06 (95% CI, 0.78-1.44) | ||
520 | |a CONCLUSIONS: rhTSH for RAI therapy is a practical option for RAI therapy in patients with intermediate- to high-risk thyroid cancer, including those with distant metastases | ||
650 | 4 | |a Meta-Analysis | |
650 | 4 | |a Systematic Review | |
650 | 4 | |a Journal Article | |
650 | 7 | |a Thyrotropin Alfa |2 NLM | |
650 | 7 | |a Iodine Radioisotopes |2 NLM | |
650 | 7 | |a Thyrotropin |2 NLM | |
650 | 7 | |a 9002-71-5 |2 NLM | |
650 | 7 | |a Thyroid Hormones |2 NLM | |
650 | 7 | |a Recombinant Proteins |2 NLM | |
700 | 1 | |a Bang, Ji-In |e verfasserin |4 aut | |
700 | 1 | |a Kim, Keunyoung |e verfasserin |4 aut | |
700 | 1 | |a Seo, Youngduk |e verfasserin |4 aut | |
700 | 1 | |a Chong, Ari |e verfasserin |4 aut | |
700 | 1 | |a Hong, Chae Moon |e verfasserin |4 aut | |
700 | 1 | |a Lee, Dong-Eun |e verfasserin |4 aut | |
700 | 1 | |a Choi, Miyoung |e verfasserin |4 aut | |
700 | 1 | |a Lee, Sang-Woo |e verfasserin |4 aut | |
700 | 1 | |a Oh, So Won |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Clinical nuclear medicine |d 1993 |g 49(2024), 3 vom: 01. Feb., Seite e96-e104 |w (DE-627)NLM000990795 |x 1536-0229 |7 nnns |
773 | 1 | 8 | |g volume:49 |g year:2024 |g number:3 |g day:01 |g month:02 |g pages:e96-e104 |
856 | 4 | 0 | |u http://dx.doi.org/10.1097/RLU.0000000000005022 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 49 |j 2024 |e 3 |b 01 |c 02 |h e96-e104 |